Drugs / Carliprazine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06589817 | Oct 2024 → Jun 2026 overdue | schizophrenia | Chengdu Kanghong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carliprazine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06589817 ↗ |
| Route | Oral | “Oral administration, once daily, with a total treatment duration of 6 weeks after successful screening.” NCT06589817 ↗ |